Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
SummaryOsteoporosis is linked to age-related decline of melatonin production; however, the direct effects of melatonin on osteoclastogenesis remain unknown. Our study demonstrates that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibits osteoclastogenesis. Melatonin-mediated anti-osteoclastogenesis involves a reactive oxygen species (ROS)-mediated but not a silent information regulator type 1 (SIRT1)-independent pathway.IntroductionOsteoporosis is a bone disorder linked to impaired bone formation and excessive bone resorption. Melatonin has been suggested to treat osteoporosis due to its beneficial actions on osteoblast differentiation. However, the direct effects of melatonin on osteoclastogenesis in bone marrow monocytes (BMMs) remain unknown. This study was to investigate whether melatonin at either physiological or pharmacological concentrations could affect osteoclast differentiation.MethodsPrimary BMMs were isolated from the femurs and tibias of C57BL/6 mice and were induced toward multinucleated osteoclasts, in the presence of melatonin at either physiological (0.01 to 10 nM) or pharmacological (1 to 100 μM) concentrations. Tartrate-resistant acid phosphatase (TRAP) staining was used to label multinucleated osteoclasts and the levels of osteoclast-specific genes were evaluated. To further explore the underlying mechanisms, the roles of silent information regulator type 1 (SIRT1) and reactive oxygen species (ROS) were evaluated.ResultsWe found that melatonin at pharmacological concentrations, rather than at physiological concentrations, significantly inhibited osteoclast formation in a dose-dependent manner. The number of TRAP-positive cells and the gene expression of osteoclast-specific markers were significantly downregulated in melatonin-treated BMMs. The melatonin-mediated repression of osteoclast differentiation involved the inhibition of the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. The treatment with SIRT1 inhibitors did not affect osteoclast differentiation but, when supplemented with exogenous hydrogen peroxide, a partial rescue of melatonin-suppressed osteoclastogenesis was observed.ConclusionMelatonin at pharmacological doses directly inhibited osteoclastogenesis of BMMs by a ROS-mediated but not a SIRT1-independent pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Tan, D., Manchester, L. C., Terron, M. P., Flores, L. J., & Reiter, R. J. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00407.x · Cited by 1,601 · cited 1×
“Melatonin protected cells from oxidative stress not only by directly scavenging free radicals [29], but also by activating intracellular antioxidant enzymes, including catalase, superoxide dismutase, and peroxidase [30].”
Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases
Callaway, D. A., & Jiang, J. X. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0656-4 · Cited by 393 · cited 1×
“In addition, reactive oxygen species (ROS) generated by RANKL have been suggested to play a crucial role in the differentiation of monocytes toward osteoclasts [13].”
Melatonin, human aging, and age-related diseases
Karasek, M. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.04.012 · Cited by 380 · cited 1×
“Melatonin production, mainly synthesized and released from the pineal gland, decreases with age and is accompanied with an increased incidence of osteoporosis [3], suggesting that there might be a relationship between the age-related decline of melatonin production and the pathological development of osteoporosis.”
Zhou, L., Chen, X., Liu, T., Gong, Y., Chen, S., Pan, G., Cui, W., Luo, Z., Pei, M., Yang, H., et al. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12250 · Cited by 158
Self-citation
Cited by
Tan, D., Xu, B., Zhou, X., & Reiter, R. (2018) · Molecules · doi:10.3390/molecules23020301 · Cited by 220
Laborda-Illanes, A., Sánchez-Alcoholado, L., Boutriq, S., Plaza-Andrades, I., Peralta-Linero, J., Alba, E., González-González, A., & Queipo-Ortuño, M. I. (2021) · Cancers · doi:10.3390/cancers13133141 · Cited by 28
“Specifically, antiaromatase therapies induce osteoporosis which could be avoided by the ingestion of melatonin, since this indoleamine promotes the proliferation of osteoblasts and the synthesis of osteoprotegerin, thus inhibiting bone resorption and increasing bone mass [98,99].”
BackgroundAberrant Tryptophan Metabolism Manipulates Osteochondral Homeostasis
Xiang, T., Yang, C., Xie, L., Xiao, S., Tang, Y., Huang, G., Sun, D., Chen, Y., & Luo, F. (2025) · Research · doi:10.34133/research.0728 · Cited by 17
Metadata
- Authors
- Zhou, L., Chen, X., Yan, J., Li, M., Liu, T., Zhu, C., Pan, G., Guo, Q., Yang, H., Pei, M., & He, F.
- Venue
- Osteoporosis International
- Published
- 2017-09-27
- Volume
- 28
- Issue
- 12
- Pages
- 3325-3337
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2758762194
- Cited by
- 64
- References
- 5
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.